Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101
Autor: | Daisuke Shimizu, Kazutaka Narui, Masatoshi Mogaki, Akihiko Suto, Tomohiko Ota, Takashi Ishikawa, Naoki Niikura, Yutaka Tokuda, Takeshi Sasaki, Mikiko Tanabe, Akimitsu Yamada, Takashi Chishima, Masaru Kuranami, Yasushi Ichikawa, Yuki Saito, Koichiro Tsugawa, Haruki Ogata, Mari S. Oba, Kumiko Kida, Hitoshi Arioka, Norihiko Sengoku, Shuichi Nawata, Yoshimasa Kosaka, Takako Doi, Itaru Endo, Satoshi Morita, Yasuhiro Suzuki |
---|---|
Rok vydání: | 2019 |
Předmět: |
Adult
Oncology endocrine system medicine.medical_specialty Cyclophosphamide Anthracycline Phases of clinical research Breast Neoplasms Triple Negative Breast Neoplasms Docetaxel Kaplan-Meier Estimate Mastectomy Segmental Risk Assessment Disease-Free Survival Drug Administration Schedule Statistics Nonparametric 03 medical and health sciences 0302 clinical medicine Breast cancer Japan Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Anthracyclines Prospective Studies 030212 general & internal medicine Triple-negative breast cancer Aged Epirubicin Dose-Response Relationship Drug business.industry General Medicine Middle Aged Prognosis medicine.disease Survival Analysis Regimen Treatment Outcome Chemotherapy Adjuvant 030220 oncology & carcinogenesis Female Surgery Fluorouracil business medicine.drug |
Zdroj: | The Breast. 47:1-9 |
ISSN: | 0960-9776 |
Popis: | Background It is important to determine whether anthracycline-containing regimens or taxane-containing regimens are more effective in individual patients. The present study compared the efficacy of six cycles of docetaxel and cyclophosphamide (TC6) with that of three cycles of 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel (FEC-D) in Japanese patients with hormone receptor (HR)-negative breast cancer (BC) to identify subtypes requiring anthracycline treatment. Methods The study included 103 patients with operable HR-negative BC. Of these patients 53 received FEC-D and 50 received TC6. The primary endpoint was pathological complete response (pCR). The secondary endpoints were safety, breast-conserving surgery, disease-free survival (DFS) and overall survival (OS). The predictive factors for each regimen were evaluated. Results Of the 103 patients, 97 completed the study (FEC-D, 50 patients; TC6, 47 patients). The pCR rate was higher with FEC-D (36%) than with TC6 (25.5%); however, the difference was not significant (P = 0.265). TC6 was safer than FEC-D, as the adverse events with docetaxel in the FEC-D regimen were similar to those with the TC6 regimen. Among patients with basal BC, the pCR rate was significantly higher with FEC-D (42.9%) than with TC6 (13.6%; P = 0.033). Among patients with triple-negative breast cancer (TNBC), the DFS and OS were significantly better with FEC-D than with TC6 (P = 0.016 and P = 0.034, respectively). Conclusion TC6 was not as effective as FEC-D for treating HR-negative BC, as TC6 was not sufficient to treat TNBC, particularly the basal subtype. Our findings suggest that anthracyclines are better treatment options than taxanes for basal BC. |
Databáze: | OpenAIRE |
Externí odkaz: |